Document Detail


Different schedules of granulocyte growth factor support for patients with breast cancer receiving adjuvant dose-dense chemotherapy: a prospective nonrandomized study.
MedLine Citation:
PMID:  21217400     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: This prospective, nonrandomized study evaluates 4 schedules of granulocyte colony-stimulating factor (G-CSF) for patients with breast cancer receiving adjuvant dose-dense chemotherapy regarding febrile neutropenia, treatment delays, and costs.
PATIENTS AND METHODS: Two hundred and thirty-one patients were enrolled to receive adjuvant dose-dense chemotherapy with 4 G-CSF schedules: filgrastim (300 mcg) days 3 to 10 [n = 84 (36.4%) group A]; days 3 to 7 [n = 26 (11.3%) group B]; days 5, 7, 9, and 11 [n = 64 (27.7%) group C], or pegfilgrastim (6 mg) on day 2 [n=57 (24.6%) group D].
RESULTS: Thirteen patients were hospitalized due to 14 episodes of febrile neutropenia; 3 in group A, 3 in group B, 1 in group C, and 6 in group D. No statistically significant difference was observed among the 4 groups. Fewer febrile neutropenic events were observed in group C than in group D (P=0.041). No statistically significant differences were observed in treatment delays or other hematological toxicities. Average overall G-CSF cost per patient in groups A and D was $8500 versus $4400 in groups B and C.
CONCLUSIONS: We found a trend in favor of the shorter G-CSF schedule. A larger, prospective randomized trial should be carried out to evaluate shorter versus standard filgrastim and pegfilgrastim schedules with regard to clinical outcomes, hematological and nonhematological toxicities, and impact in costs.
Authors:
Daniel Hendler; Shulamith Rizel; Rinat Yerushalmi; Victoria Neiman; Luisa Bonilla; Rony Braunstein; Aaron Sulkes; Salomon M Stemmer
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of clinical oncology     Volume:  34     ISSN:  1537-453X     ISO Abbreviation:  Am. J. Clin. Oncol.     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-11-22     Completed Date:  2012-01-03     Revised Date:  2012-07-05    
Medline Journal Info:
Nlm Unique ID:  8207754     Medline TA:  Am J Clin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  619-24     Citation Subset:  IM    
Affiliation:
Institute of Oncology, Davidoff Center, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel. danielh@clalit.org.il
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Breast Neoplasms* / drug therapy
Chemotherapy, Adjuvant / adverse effects
Female
Granulocyte Colony-Stimulating Factor / administration & dosage*,  economics
Humans
Male
Middle Aged
Neutropenia / chemically induced,  drug therapy*,  economics
Recombinant Proteins / administration & dosage,  economics
Chemical
Reg. No./Substance:
0/Recombinant Proteins; 0/pegfilgrastim; 121181-53-1/Filgrastim; 143011-72-7/Granulocyte Colony-Stimulating Factor
Comments/Corrections
Comment In:
Am J Clin Oncol. 2012 Jun;35(3):307   [PMID:  22609734 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Trends in Colorectal Cancer Incidence by Anatomic Site and Disease Stage in the United States From 1...
Next Document:  The effects of napping on cognitive function in preschoolers.